Page 480 - Binder2

(pg. 359) Daniell, H., Streatfield, S. J., & Wycoff, K.
(2001). Medical molecular farming: Production of
antibodies, biopharmaceuticals and edible vaccines in
plants. Trends in Plant Science, 6(5), 219–226.
https://doi.org/10.1016/S1360-1385(01)01922-7

(pg. 229) Rybicki, E. P. (2010). Plant-made vaccines for
humans and animals. Plant Biotechnology Journal, 8(5),
620–637. https://doi.org/10.1111/j.1467-7652.2009.00496.x

(pg. 71) Shukla, A. A., Wolfe, L. S., Mostafa, S. S., &
Norman, C. (2017). Evolving trends in mAb production
processes. Bioengineering & Translational Medicine, 2(1),
58–69. https://doi.org/10.1002/btm2.10058

(pg. 280) Camacho, D. M., Collins, K. M., Powers, R. K.,
Costello, J. C., & Collins, J. J. (2018). Next-generation
machine learning for biological networks. Cell, 173(7),
1581–1592. https://doi.org/10.1016/j.cell.2018.05.015

(pg. 281) Sedighian, P., et al. (2022). AI-powered
biomanufacturing platforms: Toward autonomous, adaptive
biologics production. Trends in Biotechnology, 40(8), 820–
833. https://doi.org/10.1016/j.tibtech.2022.02.009

(pg. 208) Moon, S., Bermudez, J., & t’Hoen, E. (2012).
Innovation and access to medicines for neglected
populations: Could a treaty address a broken
pharmaceutical R&D system? PLoS Medicine, 9(5),
e1001218. https://doi.org/10.1371/journal.pmed.1001218

(pg. 75) U.S. Government Accountability Office (GAO).
(2021). Drug pricing: Manufacturer discounts in the 340B
program offer benefits, but federal oversight needs
improvement. https://www.gao.gov/products/gao-21-107

478